NCT01711723View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 29, 2012

Primary Completion Date

March 25, 2013

Study Completion Date

March 25, 2013

Conditions
Atherosclerosis
Interventions
DRUG

Darapladib 160 mg

Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.

Trial Locations (2)

32809

GSK Investigational Site, Orlando

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01711723 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment | Biotech Hunter | Biotech Hunter